抗中性粒细胞胞浆抗体血管炎

别名

抗中性粒细胞胞浆抗体相关小血管炎

基本事实

患病率

1-5 / 10 000（Germany）

近两年的全球研究 706L2

2024/10 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。

• 2026-10
  [Anti-neutrophil cytoplasmic antibody-positive interstitial lung disease: rethinking classification from a disease-spectrum perspective]
  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chine · DOI · Europe PMC
• 2026-10随机对照试验
  Management of Antineutrophil Cytoplasmic Antibody-Associated Alveolar Hemorrhage: A Bayesian Reanalysis of the PEXIVAS Trial
  The Journal of rheumatology · 被引 1 · DOI · Europe PMC
• 2026-09
  Distinct molecular signature in relapsed patients with ANCA-associated vasculitis
  RMD open · DOI · Europe PMC
• 2026-09开放获取
  Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis
  RMD open · DOI · Europe PMC
• 2026-09开放获取
  Residential altitude, aerosol optical depth, and diagnostic composition of biopsy-confirmed renal diseases: a single-center renal biopsy study from Yunnan, China
  BMC nephrology · DOI · Europe PMC
• 2026-09开放获取
  Proceedings of the 33rd European Paediatric Rheumatology Congress
  Pediatric rheumatology online journal · DOI · Europe PMC
• 2026-09综述开放获取
  Immunopathogenesis of Immune Checkpoint Inhibitor-Induced Myositis, Myocarditis and Myasthenia Gravis Overlap Syndrome: A Mechanistic Synthesis of a Mitochondrial Autoantigen Hypothesis
  Cureus · DOI · Europe PMC
• 2026-09病例报告
  Levamisole-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis in paediatric nephrotic syndrome: dose-dependent and idiosyncratic risks in paediatric patients
  BMJ case reports · DOI · Europe PMC
• 2026-09开放获取
  Granular Swollen Epithelial Cells in Native Kidney Biopsies: Prevalence, Clinicopathological Associations and Kidney Outcomes
  Diagnostics (Basel, Switzerland) · DOI · Europe PMC
• 2026-09病例报告
  Rapidly progressive glomerulonephritis in rheumatoid arthritis: an early presentation of ANCA-associated vasculitis
  BMJ case reports · DOI · Europe PMC
• 2026-09开放获取
  Concomitant cryoglobulinaemic vasculitis alongside ANCA-associated vasculitis: concurrence or coincidental individual occurrence
  The Korean journal of internal medicine · DOI · Europe PMC
• 2026-09开放获取
  Clinical phenotypes of ANCA-associated vasculitis using ensemble clustering: prognostic and therapeutic insights from two Japanese cohorts
  Rheumatology (Oxford, England) · DOI · Europe PMC
• 2026-09
  Seasonal Variation in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Onset Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic: Findings From the Multicenter J-CANVAS Registry
  International journal of rheumatic diseases · DOI · Europe PMC
• 2026-09开放获取
  Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience
  Rheumatology (Oxford, England) · DOI · Europe PMC
• 2026-09开放获取
  Cardiovascular and thromboembolic risk in ANCA-associated vasculitis: a nationwide matched cohort study by disease, sex and familial risk
  Rheumatology (Oxford, England) · DOI · Europe PMC
• 2026-09病例报告
  [Progressive multifocal leukoencephalopathy associated with rituximab treatment]
  Laeknabladid · DOI · Europe PMC
• 2026-08
  Ocular Manifestations at Diagnosis of Anti-Neutrophil Cytoplasmic Anti-body-Associated Vasculitis: Clinical İmplications from a Retrospective Cohort
  Medical principles and practice : international journal of the Kuwait · DOI · Europe PMC
• 2026-08病例报告
  MPO-ANCA-associated glomerulonephritis with immune complex deposition and membranous features in a patient with Sjögren's syndrome: a case report
  CEN case reports · DOI · Europe PMC
• 2026-08
  Retraction of: Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis
  Modern rheumatology · DOI · Europe PMC
• 2026-08病例报告
  Anti-neutrophil cytoplasmic antibody-associated vasculitis presenting with acute pancreatitis, jaundice, severe anaemia and upper gastrointestinal bleed
  BMJ case reports · DOI · Europe PMC

境外已获批用于本病的药物 1L2

欧盟 0 项、美国 1 项。同一药物在两地各批一次的，会分别列出。

• Rituxan美国2011-04-19
  rituximab
  官方记录

数据来自欧洲药品管理局（EMA）的药品与罕见病用药资格公开导出表，以及美国 FDA 的罕见病用药资格数据库（Orphan Drug Product Designation Database）。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。

在中国开展的临床试验 64L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。

登记为可入组 40

• 招募中NCT05315141
  Multicenter Cohort Study of AAV in Hunan of China
  观察性 · 2022/03/16Xiangya Hospital of Central South University
  中国研究中心 1 个：Changsha
• 招募中NCT05965284
  Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
  IV 期 · 干预性 · 2023/03/09Chinese SLE Treatment And Research Group
  中国研究中心 1 个：Beijing
• 仅邀请入组NCT05859997
  Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
  不适用 · 干预性 · 2023/05/17Bioray Laboratories
  中国研究中心 1 个：Shanghai
• 招募中NCT05962840
  Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
  IV 期 · 干预性 · 2023/06/29Chinese SLE Treatment And Research Group
  中国研究中心 1 个：Beijing
• 招募中NCT05979051
  A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
  II 期、III 期 · 干预性 · 2023/11/16Guangdong Hengrui Pharmaceutical Co., Ltd
  中国研究中心 2 个：Beijing、Hangzhou
• 招募中NCT06277427
  Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
  不适用 · 干预性 · 2024/02/05Lingli Dong
  中国研究中心 1 个：Wuhan
• 招募中NCT06285279
  The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
  I 期 · 干预性 · 2024/03/04Nanjing University School of Medicine
  中国研究中心 1 个：Nanjing
• 尚未开始招募NCT06420154
  The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
  早期 I 期 · 干预性 · 2024/05/27First Affiliated Hospital of Wenzhou Medical University
  中国研究中心 1 个：Wenzhou
• 招募中NCT06350110
  Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  I 期、II 期 · 干预性 · 2024/07/10Essen Biotech
  中国研究中心 1 个：Beijing
• 招募中NCT06548607
  Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
  早期 I 期 · 干预性 · 2024/09/14Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Bengbu
• 招募中NCT06794008
  BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  II 期 · 干预性 · 2024/12/26Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06775912
  Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
  早期 I 期 · 干预性 · 2025/01/03Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Lianyungang
• 招募中NCT06614270
  Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
  不适用 · 干预性 · 2025/01/06Second Affiliated Hospital, Zhejiang University, School of Medicine
  中国研究中心 1 个：Hangzhou
• 招募中NCT06941129
  CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/02/11Institute of Hematology & Blood Diseases Hospital, China
  中国研究中心 1 个：Tianjin
• 尚未开始招募NCT06978738
  UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/05Changzhou No.2 People's Hospital
  中国研究中心 1 个：Changzhou
• 招募中NCT06978647
  A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/05/19China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Beijing
• 招募中NCT06980597
  A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/06Beijing GoBroad Hospital
  中国研究中心 2 个：Beijing
• 尚未开始招募NCT06986018
  Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
  早期 I 期 · 干预性 · 2025/06/14Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT07033299
  The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
  I 期 · 干预性 · 2025/07/01Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  中国研究中心 1 个：Wuhan
• 招募中NCT06828042
  Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
  I 期、II 期 · 干预性 · 2025/07/01Peking University Third Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT07203404
  A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
  早期 I 期 · 干预性 · 2025/07/24Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Shanghai
• 招募中NCT07104721
  A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/08/04China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Hefei
• 招募中NCT07123519
  A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/08/13China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Tianjin
• 招募中NCT07151521
  (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
  观察性 · 2025/09/01Ruijin Hospital
  中国研究中心 1 个：Shanghai
• 招募中NCT07168161
  BDB-001 Phase III Trial in ANCA-Associated Vasculitis
  III 期 · 干预性 · 2025/11/10Staidson (Beijing) Biopharmaceuticals Co., Ltd
  中国研究中心 64 个：Beijing、Cangzhou、Changchun、Changde、Changsha、Chengdu 等 42 地

另有 15 项未列出。

中国境外的在招试验 92L2

CT.gov 报告命中 92 项，此处取回并展示最近的 15 项。

• 招募中NCT07800871
  FT839 in Autoimmune Diseases
  I 期、II 期 · 干预性 · 2026/10Fate Therapeutics
  美国
• 尚未开始招募NCT07636655
  Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis
  观察性 · 2026/09/01Nantes University Hospital
  法国
• 尚未开始招募NCT07737470
  Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
  观察性 · 2026/09/01Assistance Publique - Hôpitaux de Paris
• 招募中NCT07556484
  Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
  I 期 · 干预性 · 2026/08/01Mayo Clinic
  美国
• 招募中NCT07444567
  Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
  III 期 · 干预性 · 2026/07/24AstraZeneca
  阿根廷、奥地利、比利时、加拿大、法国、印度、以色列、意大利 等 14 国
• 尚未开始招募NCT07490275
  Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2026/07/01Institute of Hematology & Blood Diseases Hospital, China
• 尚未开始招募NCT06226662
  Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
  II 期 · 干预性 · 2026/06NovelMed Therapeutics
• 招募中NCT07176546
  TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
  II 期、III 期 · 干预性 · 2026/05/22Robert Spiera, MD
  美国
• 招募中NCT07087912
  Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
  IV 期 · 干预性 · 2026/03/16University of Sao Paulo General Hospital
  巴西
• 尚未开始招募NCT07373262
  Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement
  III 期 · 干预性 · 2026/03/01University Hospital, Toulouse
  法国
• 招募中NCT07815886
  Benralizumab Effectiveness in EGPA
  观察性 · 2026/02/11European EGPA Study Group
  意大利
• 尚未开始招募NCT07451847
  Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
  IV 期 · 干预性 · 2026/02Assistance Publique - Hôpitaux de Paris
  法国
• 招募中NCT07258524
  PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
  观察性 · 2026/01/28University of Edinburgh
  英国
• 招募中NCT07251179
  Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
  观察性 · 2026/01/20University Hospital, Strasbourg, France
  法国
• 招募中NCT07089121
  Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
  I 期、II 期 · 干预性 · 2026/01/14Cartesian Therapeutics
  美国

外部标识与链接